EUVIMEDEUVIMED entdecken
Open Access

Menopausal Hormone Therapy and Subclinical Cardiovascular Disease in Women With and Without Human Immunodeficiency Virus

Brandilyn A Peters iD, David B Hanna, Anjali Sharma, Kathryn Anastos, Donald R Hoover, Qiuhu Shi, Caitlin A Moran, Elizabeth A Jackson, Maria L Alcaide, Igho Ofotokun, Adaora A Adimora, Sabina A Haberlen und 7 weitere

Clinical Infectious Diseases · 2023

DOI: 10.1093/cid/ciac620 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Brandilyn A Peters und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, USA. Hauptthemen laut MEDLINE: Cardiovascular Diseases, HIV Infections. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NHLBI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Estrogen-based hormone therapy (HT) may have beneficial cardiovascular effects when initiated in early menopause. This has not been examined in women with human immunodeficiency virus (HIV), who have heightened immune activation and cardiovascular risks.

Methods

Among 609 postmenopausal women (1234 person-visits) in the Women’s Interagency HIV Study, we examined the relationship of ever HT use (oral, patch, or vaginal) with subclinical atherosclerosis: carotid artery intima-media thickness (CIMT), distensibility, and plaque assessed via repeated B-mode ultrasound imaging (2004–2013). We also examined associations of HT with cross-sectional biomarkers of immune activation and D-dimer. Statistical models were adjusted for sociodemographic, behavioral, and cardiometabolic factors.

Results

Women (mean age, 51 years; 80% HIV positive) who ever used HT at baseline were older, and more likely to be non-Hispanic White and report higher income, than never-users. Women who ever used HT had 43% lower prevalence of plaque (prevalence ratio, 0.57 [95% confidence interval {CI}, .40–.80]; P < .01), 2.51 µm less progression of CIMT per year (95% CI, –4.60, to –.41; P = .02), and marginally lower incidence of plaque over approximately 7 years (risk ratio, 0.38 [95% CI, .14–1.03; P = .06), compared with never-users, adjusting for covariates; ever HT use was not associated with distensibility. These findings were similar for women with and without HIV. Ever HT use was associated with lower serum D-dimer, but not with biomarkers of immune activation after covariate adjustment.

Conclusions

HT may confer a subclinical cardiovascular benefit in women with HIV. These results begin to fill a knowledge gap in menopausal care for women with HIV, in whom uptake of HT is very low.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesHIV InfectionsHumansFemaleMiddle AgedCarotid Intima-Media ThicknessHIVCross-Sectional StudiesMenopauseBiomarkersRisk Factors

Stichwörter der Autor:innen

HIVatherosclerosiscardiovascular diseasehormone therapymenopause

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, USA.
  • Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA.
  • Department of Statistics and Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, New Jersey, USA.
  • School of Health Sciences and Practice, New York Medical College, Valhalla, New York, USA.
  • Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.

ORCID-Profile: Brandilyn A Peters

Förderung

  • NIAID NIH HHS
  • NHLBI NIH HHS
  • NCATS NIH HHS
  • NIA NIH HHS
  • NIMH NIH HHS
  • National Heart, Lung, and Blood Institute
  • National Institutes of Health
  • National Center for Advancing Translational Sciences

Zitieren

APA

Peters, B. A., Hanna, D. B., Sharma, A., Anastos, K., Hoover, D. R., Shi, Q., Moran, C. A., Jackson, E. A., Alcaide, M. L., Ofotokun, I., Adimora, A. A., Haberlen, S. A., Cohen, M., Tien, P. C., Michel, K. G., Levine, S. R., Hodis, H. N., Kaplan, R. C., & Yin, M. T. (2023). Menopausal Hormone Therapy and Subclinical Cardiovascular Disease in Women With and Without Human Immunodeficiency Virus. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciac620

Vancouver

Peters BA, Hanna DB, Sharma A, Anastos K, Hoover DR, Shi Q, et al. Menopausal Hormone Therapy and Subclinical Cardiovascular Disease in Women With and Without Human Immunodeficiency Virus. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciac620

BibTeX
@article{Peters2023,
  author = {Peters, Brandilyn A and Hanna, David B and Sharma, Anjali and Anastos, Kathryn and Hoover, Donald R and Shi, Qiuhu and Moran, Caitlin A and Jackson, Elizabeth A and Alcaide, Maria L and Ofotokun, Igho and Adimora, Adaora A and Haberlen, Sabina A and Cohen, Mardge and Tien, Phyllis C and Michel, Katherine G and Levine, Steven R and Hodis, Howard N and Kaplan, Robert C and Yin, Michael T},
  title = {Menopausal Hormone Therapy and Subclinical Cardiovascular Disease in Women With and Without Human Immunodeficiency Virus},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciac620}
}
Kostenlos starten →